Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNA-HER2
- Development stage
- Unknown
- Lead developer
- Labo'Life
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Sublingual
01
Overview
SNA-HER2 is a micro-immunotherapy preparation developed by Labo'Life, specifically designed to target infections caused by Herpes Simplex Virus type 2 (HSV-2). It consists of specific nucleic acids (SNA) produced at high dilutions (low doses) intended to modulate the host's immune response and interfere with viral replication. As a component of micro-immunotherapy, SNA-HER2 aims to support the immune system in controlling the virus rather than acting as a traditional high-dose antiviral. It is often used as part of complex formulations like 2LHERP to treat orofacial and genital herpes by targeting viral sequences specific to the HSV-2 strain.
- Brand names
- SNA-HER2SNA-HER-2SNA-HER 2
- Other names
- Specific Nucleic Acid-HER2SNA-HSV2SNA-HSV-2SNA-HSV 2
Beyond the preview
Go deeper on SNA-HER2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNA-HER2.